• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Background Treatment inertia is a recognised barrier to blood pressure control, and simpler,
more effective treatment strategies are needed. We hypothesised that a hypertension …

Blood pressure (BP) control rates among US adults taking antihypertensive medication have
not increased over the past decade. Many adults require 2 or more classes of …

Summary Background Single-pill combinations (SPCs) of three low-dose antihypertensive
drugs can improve hypertension control but are not widely available. A key issue for any …

Objective: The 2018 European Society of Cardiology/European Society of Hypertension
Guidelines for the management of arterial hypertension raised the need for evidence to …

Fixed-dose combination antihypertensive medications Page 1 Correspondence www.thelancet.com
Vol 394 August 24, 2019 637 their disease.Both US and European guidelines therefore …

Despite the availability of efficacious pharmacological treatments, hypertension remains the
leading global cause of death and disability, 1 and rates of blood pressure (BP) control are …

More than 70% of adults treated for primary hypertension will eventually require at least two
antihypertensive agents, either initially as combination therapy or as add-on therapy if …

Background. Raised blood pressure is the leading preventable cause of death in Australia.
One in three Australian adults (6.8 million people) have hypertension, defined as clinic or …